NCT05922904 2026-04-15
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
M.D. Anderson Cancer Center
Immunocore Ltd
Suzhou BlueHorse Therapeutics Co., Ltd.
St. Jude Children's Research Hospital
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School